✦ LIBER ✦

O-099 XYOTAX™ vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): The STELLAR 2 phase III study

✍ Scribed by Bonomi, P.; Paz-Ares, L.; Langer, C.; O'Brien, M.; Gervais, R.; Gatzemeier, U.; Reiterer, P.; Orlov, S.; Ross, H.; Vandenbulcke, J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PS13 Late breaking Paclitaxel poliglumex

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 67 KB

O-101 XYOTAX™/carboplatin vs paclitaxel/

✍ Langer, C.; O'Byrne, K.; Ross, H.; Socinski, M.; Szczesna, A.; Dediu, M.; Orlov, 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 136 KB

Phase III trial comparing paclitaxel pol

✍ Paz-Ares, L; Ross, H; O'Brien, M; Riviere, A; Gatzemeier, U; Von Pawel, J; Kauke 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 143 KB

O-2 TWO second-line docetaxel dose-sched

✍ Camps, Carlos; Massuti, Bartomeu; Jimenez, Ana Maria; Batista, Noberto; Galan, A 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 188 KB

PCN6: MODELLING THE COST-EFFECTIVENESS O

✍ P Sharplin; UK Bose; J Holmes 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB

9001 Vandetanib plus docetaxel versus do

✍ Eberhardt, W.E.E.; Johnson, B.E.; Sun, Y.; Germonpré, P.; Saijo, N.; Zhou, C.; W 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB